Please login to the form below
product withdrawal
This page shows the latest product withdrawal news and features for those working in and with pharma, biotech and healthcare.
Fertility drugs drive healthcare growth at Merck KGaA
The company put the performance in the quarter down to the withdrawal of a rival product - Ferring's Bravelle - from the US market last year because of quality issues, as well
Latest news
-
Teva suspends migraine patch on burn reports
In addition to the suspension from sale, Teva is also carrying out a pharmacy level recall of Zecuity and patients are recommended to stop using the product straight away.
-
Vioxx 'risks can be immediate'
its global withdrawal of the product (September 2004) when the cardiovascular side effects became apparent and supported by scientific evidence.
-
Communicable risk
product for which there is a reasonable possibility that the product caused a response. ... to take urgent measures (product withdrawal from the market), and assessment of product risk via life cycle management.
-
Risk nationale
Many risk management interventions were designed and implemented in reaction to new safety information, mainly in an attempt to avoid product withdrawal. ... To obtain marketing approval, firms have to provide evidence that the product is both
More from news
Approximately 1 fully matching, plus 4 partially matching documents found.
Latest Intelligence
-
Brexit implications for UK pharma legislation
on certification of clinical trials, conformity with good manufacturing practices, manufacturing inspections and, in a most ambitious deal, on product licences. ... In due course, the UK could endeavour to reach equivalence and mutual recognition
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
Real world project management
The ex-trial patients were allowed to continue access free of charge until the product was commercially available in their country. ... In contrast to this is a programme we are managing to support the global withdrawal of an oncology product.
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Market Access Director, six figure base salary and £5K joining b...
-
Highly competitive salary
- Lead Market Access Writer, £5K joining bonus, UK
-
Highly competitive salary
- Exciting Medical Writer Career Opportunity for Postdoc, Medcomms
-
Highly competitive salary
- Principal Medical Writer/ Scientific Lead, Medcomms, £5K joining...
-
Highly competitive salary
- Roche’s Polivy recommended by NICE for lymphoma therapy
- ASH 2022: bad blood but big advances
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
- AbbVie’s Rinvoq approved by MHRA for Crohn's disease
- GSK’s Benlysta given orphan drug status by FDA for systemic sclerosis
- World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
- Takeda’s dengue vaccine receives MHRA approval for those aged four years and older
- Sandoz’s biosimilar denosumab application accepted by FDA for osteoporosis
- Novartis’ Cosentyx shows continued improvement in hidradenitis suppurativa patients
- NHS urges people yet to receive their COVID-19 booster to come forward
- Biosimilars and beyond: innovating for improved patient outcomes
- Gilead’s Trodelvy approved by FDA for metastatic breast cancer
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
- Why female mentorship is so powerful in pharma
- AbbVie and Eli Lilly leave UK’s voluntary drug pricing agreement
- Europe’s cancer community publishes new report on transforming patient care
- Digital technology: a significant change in healthcare innovation
- Assessing the value of interim analyses in clinical trials
PMHub
Genetic Digital
Genetic Digital specialises in developing digital marketing solutions for the healthcare, medical and pharmaceutical sectors. From developing a digital strategy,...
Latest intelligence
- Biosimilars and beyond: innovating for improved patient outcomes
- How Europe’s biosimilar landscape has rapidly evolved over the last two decades, bringing biological medicines to more patients than ever before...
- World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
- Great Expectations – exploring the counterpoint between advances in oncology and the challenges of ensuring life-changing medicines reach patients...
- Strategic behaviour
- Strong strategising depends on your colleagues’ behaviour...
